Cathie Wood's ARK Invest has been buying shares of Recursion Pharmaceuticals, a biotech company using AI to speed up drug discovery. It is now the third-largest holding in her ARK Genomic Revolution ETF. Recursion has developed an AI-powered operating system that conducts up to 2.2 million weekly experiments to test drug candidates in an automated laboratory, advancing only the most promising compounds to clinical trials. Using AI this way could allow Recursion to launch drugs faster than competitors and license its OS to other companies, building a network effect that improves its algorithm over time.